A small study published in The New England Journal of Medicine suggests that a GLP-1 receptor agonist similar to the diabetes medication Ozempic and obesity drug Wegovy may lead to modest slowing of Parkinson’s disease symptoms. Parkinson’s expert Michael Okun called the findings “a really encouraging step forward," and Hyun Joo Cho of the National Institute of Neurological Disorders and Stroke said the study is important but further research is needed.
Full Story: The New York Times